Holen Sie sich die Stockscreener-App
1.53
1.29%
-0.02
Handel nachbörslich:
1.53
Outlook Therapeutics Inc Aktie (OTLK) Neueste Nachrichten
Press Release Distribution & PR Platform - ACCESS Newswire
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD - ADVFN
Age Related Vision Dysfunction Market to Reach New Heights - openPR.com
Age Related Vision Dysfunction Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Kodiak Sciences Inc., Outlook Therapeutics, Eye point Pharmaceuticals - The Globe and Mail
25,615 Shares in Outlook Therapeutics, Inc. (NASDAQ:OTLK) Acquired by Commonwealth Equity Services LLC - Defense World
Outlook Therapeutics Approves Retention Incentive for CFO - MSN
Henlius And Outlook Move Forward With Ophthalmic Bevacizumab - insights.citeline.com
Guggenheim maintains Buy on Outlook Therapeutics, target $10 By Investing.com - Investing.com Canada
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
FDA accepts updated biologics license application from Outlook Therapeutics for ONS-5010 for the treatment of wet AMD - Optometry Times
Guggenheim maintains Buy on Outlook Therapeutics, target $10 - Investing.com
FDA sets August 27 review date for Outlook Therapeutics’ eye drug By Investing.com - Investing.com South Africa
Outlook Therapeutics Says FDA Acknowledged Receipt Of Co's BLA ResubmissionSEC Filing - marketscreener.com
Outlook Therapeutics (OTLK) Soars After FDA Accepts ONS-5010 for Review - GuruFocus
OTLKWOutlook Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Outlook Therapeutics gets FDA review acceptance for wet AMD treatment - Seeking Alpha
Outlook Therapeutics Says FDA Accepts Biologics License Application for Wet AMD Treatment - MarketScreener
FDA sets August 27 review date for Outlook Therapeutics' eye drug - Investing.com
FDA sets August 27 review date for Outlook Therapeutics’ eye drug - Investing.com India
Outlook Therapeutics Resubmits BLA For ONS-5010 In Wet AMD - Nasdaq
Outlook Therapeutics® Announces Acceptance of Biologics - GlobeNewswire
Major FDA Milestone: Novel Wet AMD Drug Gets Review Date, Could Be First-of-its-Kind Approval - Stock Titan
Charles Schwab Investment Management Inc. Sells 15,411 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Shares Bought by Bank of New York Mellon Corp - Defense World
Head-To-Head Comparison: Cabaletta Bio (NASDAQ:CABA) vs. Outlook Therapeutics (NASDAQ:OTLK) - Defense World
Outlook Therapeutics Files Prospectus Covering Offer & Resale By Selling Stockholders Of Up To 21.7 Million Shares Of Common Stock - Marketscreener.com
Outlook Therapeutics expands share authorization - Investing.com Australia
Outlook Therapeutics Issues Convertible Note to Avondale - TipRanks
Outlook Therapeutics expands share authorization By Investing.com - Investing.com UK
Rhumbline Advisers Purchases 174,896 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
SHAREHOLDER ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire
INVESTOR ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineOTLK - ACCESS Newswire
Outlook Therapeutics® Re-Submits Biologics License - GlobeNewswire
Outlook Therapeutics Resubmits BLA For ONS-5010, A Proposed Treatment For Wet AMD - Nasdaq
Outlook Therapeutics Resubmits Biologics License Application By Investing.com - Investing.com South Africa
Outlook Therapeutics Resubmits BLA For ONS-5010 To FDA In Wet AMD - Nasdaq
Outlook Therapeutics Resubmits Biologics License Application - Investing.com
Can Outlook's Eye Treatment Win FDA Approval Despite Missing Primary Endpoint? - StockTitan
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Outlook Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024 – OTLK - ACCESS Newswire
Outlook Therapeutics (NASDAQ:OTLK) Given New $24.00 Price Target at Ascendiant Capital Markets - Defense World
HC Wainwright Issues Pessimistic Forecast for OTLK Earnings - MarketBeat
Equities Analysts Offer Predictions for OTLK Q1 Earnings - MarketBeat
vTv Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VTVT - Benzinga
HC Wainwright Has Pessimistic Outlook of OTLK Q2 Earnings - Defense World
What is HC Wainwright’s Estimate for OTLK Q1 Earnings? - Defense World
0.24%
36.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):